B12 Injection: A Literature Course in Six Modules

This course walks through the published literature on vitamin B12 injection in six modules. It describes what was studied, in whom, and what the authors reported. It does not offer instructions, protocols or outcome expectations. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment.

Module 1 — What B12 injection is and how it has been studied

Definition and class

"B12 injection" refers to the parenteral administration — most often intramuscular or subcutaneous, and in some studies perineural — of vitamin B12, also called cobalamin. Cobalamin is a water-soluble vitamin built around a corrin ring with a central cobalt atom. In the clinical literature it appears both as a replacement therapy for deficiency states and as an investigational injectable in neurological and pain conditions.

Is B12 a peptide?

No. Although B12 injections are sometimes grouped with injectable "wellness" compounds in popular writing, cobalamin is not a peptide: it is not built from amino acids linked by peptide bonds. It is a vitamin — a small-molecule cofactor. Peptide pharmacology concepts such as receptor agonism at a peptide receptor, proteolytic degradation and amino-acid sequence do not apply to it. Readers arriving from peptide topics should treat B12 as a separate chemical class with a separate literature.

Forms encountered in studies

• Cyanocobalamin — the synthetic form most commonly used in injectable deficiency-replacement products.
• Hydroxocobalamin — an injectable form used in several countries, also used at high dose in a different indication (cyanide poisoning) outside the scope of the papers reviewed here.
• Methylcobalamin (mecobalamin) — a methylated form studied as an injection in neurological disease; a 2024 report in Brain Circulation examined patients' experiences with methylcobalamin injections in amyotrophic lateral sclerosis (PMID 38655443).

How it has been studied

The study designs in the sources used for this course span a narrow range: one randomized, double-blind, placebo-controlled crossover trial in professional singers (PMID 33180098), one randomized controlled trial of B12 injection combined with traditional Chinese medicine techniques in meralgia paresthetica (PMID 41601808), a preliminary study of ultrasound-guided perineural injection after brachial plexus injury (PMID 37085967), a diagnostic-test study of B12 absorption (PMID 21623649), a review of the evidence base in Bell's palsy (PMID 26109959), and individual case reports (PMID 39897933, PMID 29850304, PMID 42063934).

Limits of the evidence — Module 1

The papers gathered here are heterogeneous: different populations, different anatomical targets, different cobalamin forms, and in several cases single patients. They do not constitute a unified evidence base, and nothing in this module establishes comparative value between cobalamin forms or between injection and oral routes.

Module 2 — Mechanism as described in the literature

The biochemical role of cobalamin is well characterised in textbooks of metabolism: two cobalamin-dependent enzymatic reactions are described in humans. Methylcobalamin serves as the cofactor for methionine synthase, which transfers a methyl group from 5-methyltetrahydrofolate to homocysteine to form methionine, linking cobalamin status to folate metabolism and methylation capacity. Adenosylcobalamin serves as the cofactor for methylmalonyl-CoA mutase in mitochondria, a step in the catabolism of certain amino acids and odd-chain fatty acids. Deficiency of the vitamin is therefore described as producing accumulation of homocysteine and methylmalonic acid, with haematological and neurological consequences.

Injection bypasses the gastrointestinal absorption pathway, which normally requires gastric acid, intrinsic factor and ileal receptor-mediated uptake. That rationale is the basis of the diagnostic question examined in a Scandinavian study, where researchers used the CobaSorb test of B12 absorption to identify patients in whom injection therapy was not required (PMID 21623649) — a framing that treats the injectable route as a workaround for impaired absorption rather than as inherently superior.

A second, distinct mechanistic idea appears in the perineural literature. Reports of ultrasound-guided perineural vitamin B12 injection in brachial plexus injury positioned the vitamin as a locally delivered agent placed around an injured nerve rather than as systemic replacement (PMID 37085967), and the same local-delivery concept was applied in a case report combining perineural vitamin B12 injection with pulsed radiofrequency of the C2 dorsal root ganglion in postherpetic neuralgia (PMID 42063934). Methylcobalamin has been discussed in neurological disease on the premise of effects relevant to nerve tissue, which is the context in which researchers documented patient experiences with methylcobalamin injections in amyotrophic lateral sclerosis (PMID 38655443).

Limits of the evidence — Module 2

Mechanistic plausibility is not clinical effect. The cofactor biochemistry explains what deficiency does; it does not demonstrate that supplying extra cobalamin to a non-deficient person or to an injured nerve changes any clinical endpoint. None of the cited human reports isolated a mechanism; they measured or described clinical observations, and several combined B12 with another intervention, which leaves mechanism inferential.

Module 3 — Reported outcomes, study by study

The table below summarises the designs and what the authors reported. Claims are restricted to what each publication stated.

Two features of this body of work stand out. First, the most rigorous design in the set — the double-blind, placebo-controlled crossover trial in singers — examined a performance endpoint in people not selected for deficiency, and the reported result did not favour the injection over placebo (PMID 33180098). Second, where enthusiasm for injections has been longstanding, as in Bell's palsy, a review found the underlying evidence to be of insufficient quality to support conclusions (PMID 26109959).

Limits of the evidence — Module 3

Sample sizes in the perineural and case literature were small or singular; the meralgia paresthetica trial studied a bundled intervention (PMID 41601808); follow-up durations varied; and no included study compared injection with an equivalent oral regimen for the same endpoint. None of these reports establishes benefit in people without documented deficiency, and no outcome described here should be read as transferable to another population or indication.

Module 4 — B12 Injection Side Effects: What Studies Report

Adverse events in the published record fall into two categories: events related to the injection procedure itself, and metabolic or systemic events reported in temporal association with an injection.

Injection-site and procedural events

A 2018 case report in Case Reports in Infectious Diseases described a subcutaneous abscess of the thigh following a vitamin B12 injection, with cultures reported as Eikenella corrodens, Actinomyces species and α-haemolytic Streptococcus (PMID 29850304). The organisms in that report are of oral-flora type, which the authors discussed in the context of how the injection was administered. Local infection, abscess formation and injection-site reactions are the class of harm most directly attributable to the act of injecting.

Systemic events reported after injection

A 2025 case report in Heliyon described hypokalemic paralysis in an adolescent following administration of dexamethasone together with a B12 injection, and the authors paired the case with a review of similar published reports (PMID 39897933). Because two agents were given, that report does not attribute causation to cobalamin alone; it documents an event in temporal association with a combined administration.

Patient-reported burdens

Beyond discrete adverse events, the practical burden of repeated parenteral administration has itself been documented: researchers collecting patients' experiences with methylcobalamin injections in amyotrophic lateral sclerosis reported on how recipients described the process of receiving the injections (PMID 38655443).

Limits of the evidence — Module 4

Case reports cannot establish incidence, and they are subject to publication bias toward unusual events. The two adverse-event reports cited here involved one patient each (PMID 29850304, PMID 39897933), and one involved co-administration of a corticosteroid. Systematic safety surveillance data were not part of the sources reviewed for this course, so no frequency, risk factor or comparative safety statement can be made from them.

Module 5 — Pharmacokinetics where data exist

The sources used here contain little formal pharmacokinetic modelling of injected cobalamin — no absorption half-life, clearance or volume-of-distribution figures were available in them, so none are reported. What the set does contain is a study of the upstream question of absorption. Researchers evaluating the CobaSorb test measured B12 absorption in order to determine which patients did not require injection therapy, and reported that the test identified such patients (PMID 21623649). Conceptually, that work addresses the main pharmacokinetic argument for the injectable route: injection is relevant where enteral absorption is impaired, and testing absorption can show when it is not impaired.

The perineural literature raises a different kinetic consideration — local rather than systemic exposure. In the ultrasound-guided perineural approach described for brachial plexus injury, the vitamin was deposited around a target nerve under imaging guidance (PMID 37085967), and a comparable local placement was described alongside pulsed radiofrequency in a C2 postherpetic neuralgia case (PMID 42063934). Local tissue concentrations, residence time and systemic spill-over from perineural deposition were not quantified in those reports.

Limits of the evidence — Module 5

No dose–exposure relationship, no comparative bioavailability figure, and no plasma-concentration time course for any cobalamin form can be drawn from the papers cited in this course. Statements about how long an injection "lasts" cannot be supported by these sources.

Module 6 — Regulatory status, stated factually

Injectable vitamin B12 is not a research chemical in most major jurisdictions; it is a long-established prescription drug category. Cyanocobalamin injection and hydroxocobalamin injection exist as approved prescription products in multiple countries, with labelling centred on vitamin B12 deficiency states, including deficiency arising from impaired intrinsic-factor-dependent absorption. Product availability, approved indication wording and prescription status differ by country and by product.

Methylcobalamin (mecobalamin) occupies a different regulatory position: it has been marketed as an approved injectable in some countries while, in others, injectable methylcobalamin is not an approved product and is encountered instead as a compounded preparation. Compounded medicines are prepared by pharmacies for an identified patient under national compounding rules; compounding is not the same as marketing approval, and compounded preparations are not reviewed for safety, efficacy or manufacturing quality in the way approved products are. Separately, some cobalamin material is offered labelled "research use only," which is a supply-chain designation for laboratory material and not an authorisation for human administration.

The research context also matters: the perineural and combination uses described in the literature — for brachial plexus injury (PMID 37085967), for meralgia paresthetica in combination with traditional Chinese medicine techniques (PMID 41601808) and for C2 postherpetic neuralgia alongside pulsed radiofrequency (PMID 42063934) — are investigational applications rather than approved labelled indications.

Limits of the evidence — Module 6

Regulatory status changes and is jurisdiction-specific; the descriptions above are general and may not reflect current rules in any particular country or state. This section is informational and is not legal advice.

What the studies did not test

Across the sources reviewed in this course, several questions were left open:

• Energy, mood or general "wellness" endpoints in people without deficiency. The one placebo-controlled trial in a non-deficient population examined vocal performance and reported no separation from placebo (PMID 33180098); broader subjective wellbeing outcomes were not tested.
• Injection versus oral supplementation head-to-head for clinical endpoints. The absorption-test work addressed who needs injections rather than which route performs better on outcomes (PMID 21623649).
• Isolated effects of B12 within combination protocols. Bundled designs did not allow separation of the vitamin's contribution (PMID 41601808, PMID 42063934).
• Long-term safety and adverse-event incidence. Harms appeared as individual case reports rather than surveillance datasets (PMID 29850304, PMID 39897933).
• High-quality evidence in conditions where injections have been used by convention. A review of Bell's palsy concluded that such evidence did not exist (PMID 26109959).
• Any peptide-related question. Cobalamin is not a peptide, so peptide-specific pharmacology was not at issue in any cited paper.

Readers comparing this literature should note the gap between how widely B12 injections are discussed and how narrow the controlled evidence in these sources is. This page is for educational purposes only and is not medical advice; consult a licensed physician about vitamin B12 status, testing or treatment.

References

• Acupuncture and vitamin B12 injection for Bell's palsy: no high-quality evidence exists (Neural Regeneration Research, 2015)
• Patients' experiences with methylcobalamin injections in amyotrophic lateral sclerosis (Brain Circulation, 2024)
• Ultrasound-Guided Perineural Vitamin B12 Injection for Brachial Plexus Injury: A Preliminary Study (Cell Transplantation, 2023)
• The vitamin B12 absorption test, CobaSorb, identifies patients not requiring vitamin B12 injection therapy (Scandinavian Journal of Clinical and Laboratory Investigation, 2011)
• Effect of Vitamin B12 Injection on the Vocal Performance of Professional Singers: A Randomized, Double-blind, Placebo-Controlled, Crossover Trial (JAMA Otolaryngology–Head & Neck Surgery, 2021)
• Hypokalemic paralysis in an adolescent following dexamethasone and B12 injection: A case report and literature review (Heliyon, 2025)
• Vitamin B12 injection plus traditional Chinese medicine techniques for meralgia paresthetica: a randomized controlled trial (Frontiers in Medicine, 2025)
• Subcutaneous Eikenella corrodens, Actinomyces sp., and α-Hemolytic Streptococcus Abscess of the Thigh following a Vitamin B12 Injection (Case Reports in Infectious Diseases, 2018)
• Combined Ultrasound-guided Perineural Vitamin B12 Injection and Pulsed Radiofrequency of C2 Dorsal Root Ganglion for Treatment of C2 Postherpetic Neuralgia: A Case Report (Journal of Medical Ultrasound, 2026)